No products in the cart.
Pre-made Glembatumumab benchmark antibody ( Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-246
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Glembatumumab biosimilar, Whole mAb ADC, Anti-GPNMB Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
| Products Name (INN Index) | Pre-Made Glembatumumab biosimilar, Whole mAb ADC, Anti-GPNMB Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody |
|---|---|
| INN Name | Glembatumumab |
| Target | GPNMB |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | CuraGen Corporation,Celldex Therapeutics Inc,National Cancer Institute (USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Brain cancer,Breast cancer,Malignant melanoma,Osteosarcoma,Squamous cell cancer,Uveal melanoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GPNMB |
| Package |
Previous slide
Next slide
